Buprefarm 10 mikrog/ time Norge - norsk - Statens legemiddelverk

buprefarm 10 mikrog/ time

orifarm generics a/s - buprenorfin - depotplaster - 10 mikrog/ time

Buprefarm 5 mikrog/ time Norge - norsk - Statens legemiddelverk

buprefarm 5 mikrog/ time

orifarm generics a/s - buprenorfin - depotplaster - 5 mikrog/ time

Buprefarm 20 mikrog/ time Norge - norsk - Statens legemiddelverk

buprefarm 20 mikrog/ time

orifarm generics a/s - buprenorfin - depotplaster - 20 mikrog/ time

Buprefarm 15 mikrog/ time Norge - norsk - Statens legemiddelverk

buprefarm 15 mikrog/ time

orifarm generics a/s - buprenorfin - depotplaster - 15 mikrog/ time

Buprefarm 30 mikrog/ time Norge - norsk - Statens legemiddelverk

buprefarm 30 mikrog/ time

orifarm generics a/s - buprenorfin - depotplaster - 30 mikrog/ time

Prepandemic influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics Den europeiske union - norsk - EMA (European Medicines Agency)

prepandemic influenza vaccine (h5n1) (surface antigen, inactivated, adjuvanted) novartis vaccines and diagnostics

novartis vaccines and diagnostics s.r.l. - influensavirusoverflateantigener (hemagglutinin og neuraminidase) av stamme a / viet nam / 1194/2004 (h5n1) - influenza, human; immunization; disease outbreaks - vaksiner - aktiv immunisering mot h5n1 subtype av influensa a-virus. , , this indication is based on immunogenicity data from healthy subjects from the age of 18 years onwards following administration of two doses of the vaccine containing a/vietnam/1194/2004 (h5n1)-like strain. , , prepandemic influenza vaccine (h5n1) novartis vaccines and diagnostic should be used in accordance with official recommendations.